阿奇霉素联合甲硝唑与甲硝唑为基础的治疗用于诱导轻中度儿童克罗恩病缓解:一项随机对照试验
这项盲法随机对照试验将73例5-18岁、10<PCDAI≤40的儿童克罗恩病患儿分为阿奇霉素联合甲硝唑组(35例)和单用甲硝唑组(38例),治疗8周。联合组第8周缓解率23/35(66%)高于单用组15/38(39%)(P=0.025),但应答率两组无显著差异(66% vs 45%,P=0.07)。联合组粪钙卫蛋白显著下降(P=0.003),单用组无显著下降(P=0.33)。
要点
- 阿奇霉素联合甲硝唑组第8周缓解率66%(23/35),高于单用甲硝唑组的39%(15/38),P=0.025。
- 两组应答率分别为66%(23/35)和45%(17/38),差异未达统计学显著(P=0.07)。
- 联合组需追加治疗者17%(6/35),低于单用组的42%(16/38),P=0.027。
核心结论
- 阿奇霉素联合甲硝唑未能改善应答率,但在诱导缓解和降低粪钙卫蛋白方面优于单用甲硝唑。
研究设计与样本
- 盲法随机对照试验,纳入73例5-18岁、10<PCDAI≤40的儿童克罗恩病患者,随机分入阿奇霉素联合甲硝唑组(35例)或单用甲硝唑组(38例),治疗8周,主要终点为意向性分析下PCDAI下降>12.5定义的应答或缓解。
主要发现
- 第8周应答率联合组23/35(66%)vs 单用组17/38(45%),P=0.07;缓解率联合组23/35(66%)vs 单用组15/38(39%),P=0.025。
- 粪钙卫蛋白在联合组显著下降(P=0.003),单用组无显著下降(P=0.33),第8周时两组比较P=0.052。
- 第8周需追加治疗者联合组6/35(17%)vs 单用组16/38(42%),P=0.027。
- 单用组12例治疗失败者接受开放标签阿奇霉素后,10/12(83%)达到缓解。
关键数值与推荐
- 阿奇霉素剂量为7.5 mg/kg,每周5天共4周,随后每周3天共4周;甲硝唑剂量为20 mg/kg/天,每日用药共8周。
- 缓解所需治疗例数(NNT)为3.7。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Crohn's disease (CD) pathogenesis associated with dysbiosis and presence of pathobionts in the lumen, intracellular compartments and epithelial biofilms. Azithromycin is active in all three compartments. Our goal was to evaluate if azithromycin-based therapy can improve response and induce remission compared with metronidazole alone in paediatric CD. DESIGN: This blinded randomised controlled trial allocated children 5-18 years with 10<Pediatric Crohn's Disease Activity Index (PCDAI)≤40 to azithromycin 7.5 mg/kg, 5 days/week for 4 weeks and 3 days/week for another 4 weeks with metronidazole 20 mg/kg/day (group 1) or metronidazole alone (group 2), daily for 8 weeks. Failures from group 2 were offered azithromycin as open label. The primary end point was response defined by a decrease in PCDAI>12.5 or remission using intention to treat analysis. RESULTS: 73 patients (mean age 13.8±3.1 years) were enrolled, 35 to group 1 and 38 to group 2. Response and remission rates at week 8 were identical 23/35 (66%) in group 1 and 17/38 (45%) and 15/38 (39%) in group 2 (P=0.07 and P=0.025, respectively). The needed to treat for remission was 3.7. Faecal calprotectin declined significantly in group 1 (P=0.003) but not in group 2 (p=0.33), and was lower at week 8 (P=0.052). Additional therapy was required in 6/35(17%) from group 1 versus 16/38(42%) in group 2 (P=0.027) by week 8. Among 12 failures in group 2, open-label azithromycin led to remission in 10/12 (83%). CONCLUSIONS: The combination of azithromycin and metronidazole failed to improve response but was superior for induction of remission and reduction in calprotectin. TRIAL REGISTRATION NUMBER: NCT01596894.
引用
- Levine A, Kori M, Kierkus J, et al. Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial. Gut. 2018. PMID: 29420227. doi:10.1136/gutjnl-2017-315199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。